The mitomycins

Anticancer Agents from Natural Products

Volumn , Issue , 2005, Pages 475-498

  Remers, William A ^a  

^a AmpliMed Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; TOXICITY;

5-FLUOROURACIL; ANTI-CANCER AGENTS; ANTICANCER DRUG; BRISTOL-MYERS; CLINICAL TRIAL; CLINICAL USE; MIXTURE COMPOUNDS; MYELOSUPPRESSION;

CHROMATOGRAPHY;

EID: 79952665488     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (162)

1. Hata, T. et al., Mitomycin, a new antibiotic from streptomyces, J. Antibiot. (Jpn.), Ser. A, 9, 141, 1956.
2. Wakaki, S. et al., Isolation of new fractions of antitumor mitomycins, Antibiot. Chemother. 8, 288, 1958.
3. Frank, W. and Osterberg, A.E., Mitomycin C (NSC-26988) — an evaluation of the Japanese reports, Cancer Chemother. Rep., 9, 114, 1960.
4. Jones, Jr., R., Mitomycin C. A preliminary report of studies of human pharmacology and initial therapeutic trial, Cancer Chemother. Rep. 2, 3, 1959.
5. Sutow, W.W. et al., Evaluation of dosage schedules of mitomycin C (NSC-26988) in children, Cancer Chemother. Rep., Part 1, 55, 285, 1971.
6. Webb, J.S. et al., The structures of mitomycins A, B, C, and porfiromycins — parts I and II, J. Am. Chem. Soc., 84, 3185, 3186, 1962.
7. Yahashi, R. and Matsubara, I., The molecular structure of 7-demethoxy-7-p-bromoanilino mitomycin B, J. Antibiot (Tokyo), 29, 10, 1976.
8. Urakawa, C. et al., Mitomycin derivatives, Jpn. Kokai Tokkyo Koho, 1980.
9. Kono, M. et al., Albomitomycin A and isomitomycin A: products of novel intramolecular rearrangement of mitomycin A, J. Am. Chem. Soc., 109, 7224, 1987.
10. Feigelson, G.B. et al, On the reaction of leucomitosenes with osmium tetroxide. A route to novel mitomycins, J. Org. Chem., 1988, 53, 3390.
11. Tulinsky, A. and van den Hende, J.H., The crystal and molecular structure of n-brosylmitomycin A, J. Am. Chem. Soc., 89, 2905, 1967.
12. Taylor, W.G. and Remers, W.A., Structures and stereochemistry of mitomycin hydrolysis products, Tetrahedron Lett., 2483, 1974.
13. Rebek, J. et al., Total synthesis of a mitosene, J. Org. Chem., 49, 5164, 1984.
14. Garrett, E.R., The physical chemical characterization of the products, equilibria, and kinetics of the complex transformations of the antibiotic porfiromycin, J. Med. Chem., 6, 488, 1963.
15. Kinoshita, S. et al., Chemical transformations of mitomycins: structure-activity relation of mitomycin derivatives, Prog. Antimicrob. Anticancer Chemother. 2, 112, 1970.
16. Underberg, W.J.M. and Lingeman, H., Aspects of chemical stability of mitomycin and porfiromycin in solution, J. Pharm. Sci., 72, 549, 1974.
17. Schiltz, P. and Kohn, H., Studies on the reactivity of reductively activated mitomycin C, J. Am. Chem. Soc., 115, 10510, 1993.
18. Hornemann, Ho Y.-K., Mackey, Jr., J.K., and Srivastava, S.C., Studies on the mode of action of mitomycin antibiotics. Reversible conversion of mitomycin C into sodium 7-aminomitosane-9asulfonate, J. Am. Chem. Soc., 98, 7069, 1976.
19. Han, I., Russell, D.J., and Kohn, H., Studies on the mechanism of mitomycin C(1) electrophilic transformations: structure-activity relationships, J. Org. Chem., 57, 1799, 1992.
20. Wang, S. and Kohn, H., Studies on the mechanism of activation of C(7) ethylenediamine substituted mitomycins. Relevance of the proposed mode of action of BMY-25067 and KW-2149, Tetrahedron Lett., 37, 2337, 1996.
21. Wang, S. and Kohn, H., Mitomycin betaines: synthesis, structure and solvolytic reactivity, J. Org. Chem., 61, 9202, 1996.
22. Pan, S.-S. et al., Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase, J. Biol. Chem., 259, 959, 1984.
23. Danishefsky, S.J. and Egbertson, M., The characterization of intermediates in the mitomycin activation cascade: a practical synthesis of an aziridinomitosene, J. Am. Chem. Soc., 108, 4648, 1986.
24. Hoey, B.M., Butler, J., and Swallow, A.J., Reductive activation of mitomycin C, Biochemistry, 27, 2608, 1988.
25. Kirsch, E.J. and Korshalla, J.D., Influence of biological methylation on the biosynthesis of mitomycin A, J. Bacteriol., 87, 247, 1964.
26. Hornemann, U. et al., D-Glucosamine and L-citrulline, precursors in mitomycin biosynthesis by Streptomyces verticillatus, J. Am. Chem. Soc., 96, 320, 1974.
27. Mao, Y., Varoglu, M., and Sherman, D.H., Mitomycin resistance in Streptomyces lavendulae includes a novel drug-binding-protein-dependent export system, J. Bact., 181, 2199, 1999.
28. Kim, C.G. et al., Formation of 3-amino-5-hydroxybenzoic acid, the precursor of mC7 units in ansamycin antibiotics, by a new variant of the shikimate pathway, J. Am. Chem. Soc., 111, 4941, 1992.
29. Islam, I. and Skibo, E.B., Synthesis and physical studies of azamitosene and iminoazamitosene reductive alkylating agents. Iminoquinone hydrolytic stability, syn/anti isomerization, and electrochemistry, J. Org. Chem., 55, 3195, 1990.
30. Islam, I. et al, Structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles: new reductive alkylating DNA cleaving agents, J. Med. Chem., 34, 2994, 1991.
31. Huang, X., Suleman, A., and Skibo, E.B., Rational design of pyrrolo[1,2-a]benzimidazole based antitumor agents targeting the DNA major groove, Bioorg. Chem., 28, 324, 2000.
32. Mercado, C.M. and Tomasz, M., Inhibitory effects of mitomycin-related compounds lacking the C1-C2 aziridine ring, Antimicrob. Agents Chemother., 1, 73, 1972.
33. Szybalski, W. and Iyer, V.N., The mitomycins and porfiromycin, in Antibiotics I, Mechanism of Action, Gottlieb, D. and Shaw, P.D., Eds., Springer, New York, 1967, pp. 221-245.
34. Iyer, V.N. and Szybalski, W., Mode of interaction of mitomycin C with deoxyribonucleic acid and other polynucleotides in vitro, Science, 145, 55, 1964.
35. Tomasz, M. et al., Mode of interaction of mitomycin C with deoxyribonucleic acid and other polynucleotides in vitro, Biochemistry, 13, 4878, 1974.
36. Gustafson, D.L. and Pritsos, C.A., Kinetics and mechanism of mitomycin C bioactivation by xanthine dehydrogenase under aerobic and hypoxic conditions, Cancer Res., 53, 5470, 1993.
37. Wang, X. et al., Enhanced cytotoxicity of mitomycin C in human tumor cells with inducers of DTdiaphorase, Br. J. Cancer, 80, 1223, 1999.
38. Sagara, N. and Katoh, M., Mitomycin C resistance induced by TCF-3 overexpression in gastric cancer cell line MKN28 is associated with DT-diaphorase down regulation, Cancer Res., 60, 5959, 2000.
39. Belcourt, M.F. et al., Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytotcrome (P-540) reductase, Proc. Natl. Acad. Sci. USA, 93, 456, 1996.
40. Moore, H.W., Bioactivation as a model for drug design bioreductive alkylation, Science, 197, 527, 1977.
41. Li, V.-S. et al., Structural requirements for mitomycin C DNA binding, Biochemistry, 34, 7120, 1995.
42. Boruah, R.C. and Skibo, E.B., Mitomycin C redox couple pKa values studied by spectrophotometric titration, pH rate profiles, and Nernst-Clark plots, J. Org. Chem., 60, 2232, 1995.
43. Tomasz, M. et al., Isolation and characterization of a major adduct between mitomycin C and DNA, J. Am. Chem. Soc., 110, 5892, 1988.
44. Tomasz, M., Chawla, A.K., and Lipman, R., Mechanism of monofunctional and bifunctional alkylation of DNA by mitomycin C, Biochemistry, 27, 3182, 1988.
45. Tomasz, M. et al., Full structure of a mitomycin C dinucleotide adduct. Use of differential FT-IR spectroscopy in microscale structural studies, J. Am. Chem. Soc., 105, 2059, 1983.
46. Verdine, G.L. and Nakanishi, K., Use of differential second-derivative UV and FTIR spectroscopy in structural studies with multichromophoric compounds, J. Am. Chem. Soc., 107, 6118, 1985.
47. Tomasz, M. et al., Reassignment of the guanine-binding mode of reduced mitomycin C. Biochemistry, 25, 4337, 1986.
48. Tomasz, M. et al., Reaction of DNA with chemically or enzymatically activated mitomycin C: isolation and structure of the major covalent adduct, Proc. Natl. Acad. Sci. USA, 83, 670, 1986.
49. Borowy-Borowski, H. et al., Duplex oligodeoxyribonucleotides crosslinked by mitomycin C at a single site: synthesis, properties, and crosslink, Biochemistry, 19, 2992, 1990.
50. Norman, B. et al., NMR and computational characterization of mitomycin cross-linked to adjacent deoxyguanosines in the minor groove of the d(TACGA).d(TACGA) duplex, Biochemistry, 29, 2861, 1990.
51. Weidner, M.F., Millard, J.T., and Hopkins, P.B., Determination at single-nucleotide resolution of the sequence specificity of DNA interstrand cross-linking agents in DNA fragments, J. Am. Chem. Soc., 111, 9720, 1989.
52. Rao, S.N., Singh, U.C., and Kollman, P.A., Conformations of the noncovalent and covalent complexes between mitomycins A and C and d(GCGCGCGCGC)2, J. Am. Chem. Soc., 108, 2058, 1986.
53. McGuiness, B.F. et al., Reductive alkylation of DNA by mitomycin A, a mitomycin with high redox potential, Biochemistry, 30, 6444, 1991.
54. Remers, W.A. et al., Conformations of complexes between mitomycins and decanucleotides. 3. Sequence specificity, binding at C-10, and mitomycin analogs, J. Med. Chem., 31, 1612, 1988.
55. Teng, S.P., Woodson, S.A., and Crothers, D.M., DNA sequence specificity for mitomycin crosslinking, Biochemistry, 28, 3901, 1989.
56. Borowy-Borowski, H., Lipman, R., and Tomasz, M., Recognition between mitomycin C and specific double-strand DNA sequences for cross-link formation, Biochemistry, 29, 2999, 1990.
57. Kumar, S., Johnson, W.S., and Tomasz, M., Orientation isomers of the mitomycin C interstrand crosslinks in non-self-complementary DNA. Differential effect of two isomers on restriction endonuclease cleavage at a nearby site, Biochemistry, 32, 1364, 1993.
58. Kumar, S., Lipman, R., and Tomasz, M., Recognition of specific DNA sequences by mitomycin C for alkylation, Biochemistry, 31, 1399, 1992.
59. Li, V.-S. et al., Role of the C-10 subsituent in mitomycin C-1-DNA binding, J. Am. Chem. Soc., 118, 2326, 1996.
60. Kohn H. et al., On the origins of the DNA sequence selectivity of mitomycin monoalkylation transformations, J. Am. Chem. Soc., 114, 9218, 1992.
61. Kumar, S.G. et al., Mitomycin C-DNA adducts generated by DT-diaphorase. Revised mechanism of the enzymatic reductive activation of mitomycin C, Biochemistry, 36, 14128, 1997.
62. Kumar, G.S. et al., Binding of 2,7-diaminomitosene to DNA: Model for recognition of DNA by activated DNA, Biochemistry, 34, 2662, 1995.
63. Kumar, G.S. et al., 2,7-Diaminomitosene, a monofunctional mitomycin C derivative, alkylates DNA in the major groove. Structure and base-sequence specificity of the DNA adduct and mechanism of alkylation, J. Am. Chem. Soc., 118, 9209, 1996.
64. Palom, Y. et al., Relative toxicities of DNA cross-links and monoadducts: new insights from studies of decarbamoyl mitomycin C and mitomycin C, Chem. Res. Tox., 15, 1398, 2002.
65. Gargulio, D. et al., Alkylation and crosslinking of DNA by the unnatural enantiomer of mitomycin C: mechanism of the DNA-sequence specificity of mitomycins, J. Am. Chem. Soc., 117, 9388, 1995.
66. Maliepaard, M. et al., Mitosene-DNA adducts. Characterization of two major DNA adducts formed by 1,10-bis(acetoxy)-7-methoxymitosene upon reductive activation., Biochemistry, 36, 9211, 1997.
67. Ouyang, A. and Skibo, E., The iminium ion chemistry of mitosene DNA alkylating agents. Enriched 13C-NMR studies, Biochemistry, 39, 5718, 2000.
68. Xing, C. and Skibo, E.B., Sigmatropic reactions of the aziridinyl semiquinone species. Why aziridinyl benzoquinones are metabolically more stable than aziridinyl indoloquinones, Biochemistry, 39, 10770, 2000.
69. Millard, J.T. and Beachy, T.M., Selective recognition of m5Cpg dinucleotide sequence in DNA by mitomycin C for alkylation and crosslinking, Biochemistry 32, 12850, 1993.
70. Tomasz, M. et al., The purine 2-amino group as the critical recognition element for sequence-specific alkylation and crosslinking of DNA by mitomycin C, J. Am. Chem. Soc., 120, 11581, 1998.
71. Sharma, M. and Tomasz, M., Conjugation of glutathione and other thiols with bioreductively activated mitomycin C. Effect of thiols on reductive activation rate, Chem. Res. Toxicol., 7, 390, 1994.
72. Sharma, M., He, Q.-Y., and Tomasz, M., Effects of glutathione on alkylation and crosslinking of DNA by mitomycin C. Isolation of a ternary glutathione-mitomycin-DNA adduct, Chem. Res. Toxicol., 7, 401, 1994.
73. Xu, B.H., Gupta, V., and Singh, S.V., Mitomycin sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance, Arch. Biochem. Biophys., 308, 164, 1994.
74. Basu, A.K. et al., Effect of site specifically located mitomycin C-DNA monoadducts on in vitro DNA synthesis by DNA polymerases, Biochemistry, 32, 4708, 1993.
75. Abbas, T. et al., Differential activation of p53 by the various adducts of mitomycin C, J. Biol. Chem., 277, 40513, 2002.
76. Skibo, E.B. and Schultz, W.G., Pyrrolo[1,2-a]benzimidazole based aziridinyl quinones, J. Med. Chem., 36, 3050, 1993.
77. Schultz, W.G., Nieman, R.A., and Skibo, E.B., Evidence for DNA phosphate backbone alkylation and cleavage by pyrrolo[1,2-a]benzimidazoles, small molecules capable of causing sequence specific phosphodiester bond hydrolysis, Proc. Natl. Aced. Sci. USA, 92, 11854, 1995.
78. Bachur, N.R., Gordon, S.L., and Gee, M.V., A general mechanism for microsomal activation of quinone anticancer agents to free radicals, Cancer Res., 38, 1745, 1978.
79. Tomasz, M., Hydrogen peroxide generation during the redox cycle of mitomycin C and DNA-bound mitomycin C, Chem. Biol. Interact., 13, 89, 1976.
80. Lown, J.W., The molecular mechanism of antitumor action of the mitomycins, in Mitomycin C, Current Status and New Developments, Carter, S.T. and Crooke, S.T., Eds., Academic Press, Orlando, FL, 1979, pp. 5-26.
81. Ueda, K. et al., Inactivation of bacteriophage NX174 by mitomycin C in the presence of sodium hydrosulfite and cupric ions, Chem. Biol. Interact., 29, 145, 1980.
82. Pan, S.-S., Andrews, P.A., and Bachur, N.R., Reduction of mitomycin C by NADPH cytochrome p450 reductase and xanthine oxidase, Fed. Proc., 41, 1541, 1982.
83. Hashimoto, Y., Shudo, K., and Okamoto, T., Structures of modified nucleotides isolated from calf thymus DNA alkylated with reductively activated mitomycin C, Tetrahedron Lett., 23, 677, 1982.
84. Pritsos, C.A. and Sartorelli, A.C, Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics, Cancer Res., 46, 3528, 1986.
85. Remers, W.A. and Dorr, R.T. in The Alkaloids: Chemical and Biological Perspectives, Pelletier, S.W., Ed., Wiley, New York, 1988, Vol. 6.
86. Kinoshita, S. et al., Mitomycin derivatives. 1. Preparation of mitosane and mitosene compounds and their biological activities, J. Med. Chem., 14, 103, 1971.
87. Kinoshita, S. et al., Mitomycin derivatives. 2. Derivatives of decarbamoylmitosane and decarbamoylmitosene, J. Med. Chem., 14, 109, 1971.
88. Kojima, R. et al., Some structure-activity relationships for mitomycin C (NSC-26980) derivatives in the treatment of l1210 leukemia, Cancer Chemother. Rep., 3, 121, 1972.
89. Iyengar, B.S. et al., Mitomycin C and porfiromycin analogs with substituted ethylamines at position 7 J. Med. Chem., 26, 16, 1983.
90. Imai, R. et al., Antitumor activity of 7-N-phenyl derivatives of mitomycin C in the leukemia p388 system, Gann, 71, 560, 1980.
91. Iyengar, B.S. et al., Development of new mitomycin C and porfiromycin analogs. J. Med. Chem., 24, 975, 1981.
92. Iyengar, B.S. et al., Mitomycin C analogs with secondary amines at position 7, J. Med. Chem., 26, 1453, 1983.
93. Sami, S.M. et al., Mitomycin C analogs with aryl substituents on the 7-amino group, J. Med. Chem., 27, 701, 1984.
94. Iyengar, B.S. et al., Metal complexes of mitomycins, J. Med. Chem., 29, 144, 1986.
95. Kunz, K.R. et al., Structure-activity relationships for mitomycin C and mitomycin A analogs, J. Med. Chem., 34, 2281, 1991.
96. Ishioka, C. et al., Comparative studies on the action of 7-N-[2-[[2-(-L-glutamylamino) ethyl]dithio]ethyl]mitomycin C and of mitomycin C on cultured NL60-cells and isolated phage and plasmid DNA, Cancer Chemother. Pharmacol., 26, 117, 1990.
97. Bradner, W.T. et al, Antitumor activity and toxicity in animals of N-7[2-(4-nitrophenyldithio)ethyl]mitomycin C (BMY-25067), Invest. New Drugs, 8, 51, 1990.
98. Bradner, W.T. et al., Antitumor activity and toxicity in animals of RR-150 (7-cysteaminomitosane), a new mitomycin derivative, Cancer Res., 44, 5619, 1984.
99. Sami, S.M. et al., Preparation and antitumor activity of new mitomycin A analogs, J. Med. Chem., 30, 168, 1987.
100. Li, V.-S. et al., The role of the C-10 substituent in mitomycin C-1-DNA binding, J. Am. Chem. Soc., 118, 2326, 1966.
101. Takanagi, H. et al., One step preparation of 6-demethyl-6-formylmitomycin C and cytotoxicity of its derivatives, J. Antibiot., 45, 1815, 1992.
102. Iyengar, B.S., Remers, W.A., and Bradner, W.T., Preparation and antitumor activities of 7-substituted-1,2-aziridinomitosenes, J. Med. Chem., 29, 1864, 1986.
103. Fost, D.L., Ekwuribe, N.N., and Remers, W.A., Synthesis of 1-substituted-7-methoxymitosenes, Tetrahhedron Lett., 131, 1973.
104. Taylor, W.G. et al., Mitomycin antibiotics. Synthesis and antineoplastic activity of mitosene analogs of the mitomycins, J. Med. Chem, 24, 1184, 1981.
105. Casner, M.L., Remers, W.A., and Bradner, W.T., Synthesis and biological activity of 6-substituted analogs of the mitomycins, J. Med. Chem, 28, 921, 1985.
106. Hodges, J.C., Remers, W.A., and Bradner, W.T., Synthesis and antineoplastic activity of mitosene analogs of the mitomycins, J. Med. Chem, 24, 1184, 1981.
107. Allen, Jr., G.R., Poletto, J.F., and Weiss, M.J., The mitomycin antibiotics. Synthetic studies. II. Synthesis of 7-methoxymitosene, an antibacterial agent, J. Am. Chem. Soc., 86, 3878, 1964.
108. Allen, Jr., G.R., Poletto, J.F., and Weiss, M.J., The mitomycin antibiotics. Synthetic studies. XV. The preparation of a related indoloquinone, J. Med. Chem., 10, 1, 1967.
109. Allen, Jr., G.R. and Weiss, M.J., The mitomycin antibiotics. Synthetic studies XVII. Preparation of 1-(β-substituted ethyl)indoloquinone analogs, J. Med. Chem., 10, 23, 1967.
110. Remers, W.A., Roth, R.H., and Weiss, M.J., The mitomycin antibiotics. Synthetic studies. VIII. Indoloquinone analogs with variations at C-5, J. Org. Chem., 31, 1012, 1966.
111. Iwata, H. and Goldberg, E.P., Tissue-binding macromolecular antitumor drugs for localized therapy: mitomycin C-concanavalin A conjugates, Polymer Reprints, 24, 73, 1983.
112. Kaneko, Y., Tanaka, T., and Iguchi, S., Preparation and properties of a mitomycin C-albumin conjugate, Chem. Pharm. Bull., 38, 2614, 1990.
113. Umemoto, N. et al., Conjugates of mitomycin C with the immunoglobulin M monomer fragment of a monoclonal anti-MM46 immunoglobulin M antibody with or without serum albumin as intermediary, J. Appl. Biochem., 6, 297, 1984.
114. Tsukada, Y., Characterization of human AFP producing stomach cancer xenotransplanted in nude mice and the effect of mitomycin C and antibody to human AFP of this tumor, Nippon Shokakibyo Gakki Zasshi, 82, 18, 1985.
115. Li, S. et al., Preparation of antigastric cancer monoclonal antibody MGb2-mitomycin C conjugate with improved antitumor activity, Bioconjugate Chem., 1, 245, 1990.
116. Tanaka, J.-I. et al., Preparation of a conjugate of mitomycin C and anti-neural cell adhesion molecule monoclonal antibody for specific chemotherapy against biliary tract carcinoma, Surg. Today, 28, 1217, 1998.
117. Huh, N. et al., Design, synthesis, and evaluation of mitomycin-tethered phosphorothioate oligodeoxynucleotides, Bioconjugate Chem., 7, 659, 1996.
118. Paz, M.M, Das, A., and Tomasz, M., Mitomycin C linked to minor groove binding agents: synthesis, reductive activation, DNA binding and cross-linking properties and in vitro antitumor activity, Bioorg. Med. Chem., 7, 2713, 1999.
119. Okamoto, H. et al., Effect of 1-alkyl or 1-alkenyl-azocycloalkanone derivatives on penetration of mitomycin C through rat skin, Chem. Pharm. Bull., 35, 4605, 1987.
120. Shikano, M. et al., 1a-Docosahexaenoyl mitomycin C: a novel inhibitor of protein tyrosine kinase, Biochem. Biophys. Res. Commun., 248, 858, 1998.
121. Nagai, K. et al., Synthesis and antitumor activities of mitomycin C (1-3)-beta-D-glucan conjugate, Chem. Pharm. Bull., 40, 986, 1992.
122. Ghiorghis, A., Talebaum, A., and Clarke, R., In vitro antineoplastic activity of C-7-substituted mitomycin C analogs MC-77 and MC-62 against human breast-cancer cell lines, Cancer Chemother. Pharmacol., 29, 290, 1992.
123. Yan, Z. et al., Synthesis of the anticancer drug mitomycin C-dextran conjugate with affinity to lymph and studies on its biological properties, Zhongguo Yaowu Huaxue Zashi, 9, 240, 1999.
124. Hoste, K., Schacht, E., Rihova, B., Synthesis and biological evaluation of PEG-substituted macromolecular prodrugs from mitomycin C, J. Bioactive Compatible Polymers, 17, 123, 2002.
125. Kato, Y., Onishi, H., and Machida, Y., A novel water-soluble N-succinyl-chitosan-mitomycin C conjugate prepared by direct carbodiimide coupling: physicochemical properties, antitumor characteristics, and systemic retention, S.T.P. Pharma Sci., 10, 133, 2000.
126. Zalipsly, S. et al., New liposomal prodrug of mitomycin C, Proceedings of the 28th International Symposium on Controlled Release of Bioactive Materials and 4th Consumer Diversified Products Conference, San Diego, CA, June 23–27, 2001.
127. Iyengar, B.S. et al., Nucleotide derivatives of 2,7-diaminomitosene, J. Med. Chem., 31, 1612, 1988.
128. Iyengar, B.S., Dorr, R.T., and Remers, W.A., Additional nucleotide derivatives of mitosenes. Synthesis and activity against parenteral and multidrug resistant L1210 leukemia, J. Med. Chem., 34, 1947, 1991.
129. Sami, S.M. et al., Preparation and antitumor activity of new mitomycin A analogs, J. Med. Chem., 30, 168, 1987.
130. Bradner, W.T., Remers, W.A., and Vyas, D.M., Structure-activity comparison of mitomycin C and mitomycin A analogs, Anticancer Res., 9, 1095, 1989.
131. Bradner, W.T. et al., Antitumor activity and toxicity in animals of BMY-25282, a new mitomycin derivative, Cancer Res., 45, 6475, 1985.
132. Remers, W.A., Mitomycins, in Anticancer Agents Based on Natural Product Models, Cassady, J.M and Douros, J.D., Eds., Academic Press, New York, 1980, Chapter 4.
133. Orlamans, E.O. et al., Synthesis, mechanism of action, and biological evaluation of mitosenes, J. Med. Chem., 32, 1612, 1989.
134. Weiss, M.J. et al., The mitomycin antibiotics. Synthetic studies. XXII. Antibacterial structure-activity relationships in the indoloquinone series, J. Med. Chem., 11,742, 1968.
135. Allen, Jr., G.R., Poletto, J.F., and Weiss, M.J., Mitomycin antibiotics. Synthetic studies. III. Related indoloquinones, active antibacterial agents, J. Am. Chem. Soc., 86, 3878, 1964.
136. Allen, Jr., G.R., Poletto, J.F., and Weiss, M.J., Mitomycin antibiotics, Synthetic studies. XVII. Indoloquinones with variants at the 2 position, J. Org. Chem., 30, 2897, 1965.
137. Poletto, J.F., Allen, Jr., G.R., and Weiss, M.J., Mitomycin antibiotics. Synthetic studies. XIX. Synthesis of indoloquinone analogs with certain C-3 variants, J. Med. Chem., 10, 95, 1967.
138. Leadbetter, G. et al., Mitomycin antibiotics. Synthesis of 1-substituted 7-methoxymitosenes, J. Org. Chem., 39, 3508, 1974.
139. Hirata, T., Yamada, Y., and Matsui, M., Synthetic studies on mitomycins. Synthesis of aziridinopyrrolo[ 1,2-a]indoles, Tetrahedron Lett., 19, 1969.
140. Siuta, G.J., Franck, R.W., and Kempton, R.J., Studies directed toward a mitomycin synthesis, J. Org. Chem., 39, 3739, 1974.
141. Kametani, T. et al., Photooxygenation of 9-keto-7-methoxy-6-methyl-9H-pyrrolo[1,2-a]indole as a synthetic approach to mitomycins, Heterocycles, 4, 1637, 1976.
142. Nakatsubo, F. et al., Synthetic studies toward mitomycins. 2. Total synthesis of dl-porfiromycin, J. Am. Chem. Soc., 99, 8115, 1977.
143. Fukuyama, T. et al., Synthetic studies toward mitomycins. III. Total synthesis of mitomycins A and C, Tetrahedron Lett., 4295, 1977.
144. Fukuyama, T. and Yang, L., Practical synthesis of (±)–mitomycin C, J. Am. Chem. Soc., 111, 8303, 1989.
145. Danishefsky, S., Chemical explorations driven by an enchantment with mitomycinoids — a twenty year account, Synlett, 475, 1995.
146. Benbow, J.W., McClure, K.F., and Danishefsky, S.J., Intramolecular cycloaddition reactions of dienyl nitroso compounds: application to the synthesis of mitomycin K, J. Am. Chem. Soc., 115, 12305, 1993.
147. McClure, K.F. and Danishefsky, S.J., A novel Heck arylation reaction: rapid access to congeners of FR 900482, J. Am. Chem. Soc., 115, 6094, 1993.
148. Moertel, C.G., Reitemeir, R.J., and Hahn, R.G., Mitomycin C therapy in advanced gastrointestinal cancer. J. Am. Med. Assoc., 204, 1045, 1968.
149. Doll, D.C., Weiss, R.B., and Issel, B.F., Mitomycin: ten years after approval for marketing, J. Clin. Oncol., 3, 276, 1985.
150. Miller, T.P., McMahon, L.J., and Livingston, R.B., Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vincristine, and mitomycin C. Cancer Treat. Rep., 64, 1241, 1980.
151. Crooke, S.T. and Bradner, W.T., Mitomycin C: a review. Cancer Treat. Rev., 3, 121, 1976.
152. Early, K. et al., Mitomycin C in the treatment of metastatic transitional cell carcinoma of urinary bladder. Cancer, 31, 1150, 1973.
153. Baker, L.H., Opipari, M.I., and Izbicki, R.M., Phase II study of mitomycin C, vincristine, and bleomycin in advanced squamous cell carcinoma of the uterine cervix, Cancer, 38, 2222, 1976.
154. MacDonald, J. et al., 5-Fluorouracil (5-FU), mitomycin C (MMC), and Adriamycin (ADR) — FAM: a new combination chemotherapy program for advanced gastric carcinoma (abstract C-11), Proc. Am. Soc. Clin. Oncol., 17, 244, 1976.
155. Dorr, R.T. and Von Hoff, D.D., Cancer Chemotherapy Handbook, Appleton and Lange, Norwalk, CT, 1994, p. 719.
156. Kaplan, M.A. and Vyas, D.M., Crystalline 7-(dimethylaminomethylene)amino-9a-methoxymitosane, Ger. Offen. DE 3,605,523, 1986.
157. Bradner, W.T. et al., Antitumor activity and toxicity in animals of BMY-25282, a new mitomycin derivative, Cancer Res., 45, 6475, 1985.
158. Bradner, W.T. et al., Antitumor activity and toxicity in animals of RR-150 (7-cysteaminomitosane), a new mitomycin derivative, Cancer Res., 44, 5619, 1984.
159. Senter, P.D. et al., Reassignment of the structure of the antitumor agent RR-150, J. Antibiot., 41, 199, 1988.
160. Vyas, D.M. et al., Novel disulfide mitosanes as antitumor agents, Recent Adv. Chemother, Proc. Int. Congr. Chemother 14th, Anticancer Sect. 1, 517, 1985.
161. Bradner, W.T. et al., Antitumor activity and toxicity in animals of N-7-[2-(4-nitrophenyldithio) ethyl]mitomycin C (BMY-25067), Invest. New Drugs, 8, S1-S7, 1990.
162. De Boer, C. et al., Porfiromycin, a new antibiotic, Antimicrobial. Agents Annual, 1960, Plenum Press, New York, 1961, pp. 17-22.